A phase II clinical trial to evaluate the efficacy of the antiviral vaccine GP120 depleted HIV 1 vaccine [RG 83894] in antiretroviral-naive patients with HIV infection.

Trial Profile

A phase II clinical trial to evaluate the efficacy of the antiviral vaccine GP120 depleted HIV 1 vaccine [RG 83894] in antiretroviral-naive patients with HIV infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs GP120-depleted HIV-1 vaccine (Primary) ; Vaccines
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms Study215
  • Sponsors Orchestra Therapeutics
  • Most Recent Events

    • 30 Dec 2016 Results published in the Immune Response BioPharma Media Release.
    • 01 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top